ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Jatenzo, an Oral Testosterone Replacement Therapy
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 192050" data-attributes="member: 13851"><p>[URL unfurl="true"]https://www.globenewswire.com/news-release/2020/12/07/2140624/0/en/Clarus-Announces-JATENZO-Testosterone-Undecanoate-Capsules-CIII-Now-Covered-by-Express-Scripts.html[/URL]</p><p></p><p><span style="font-size: 26px"><strong>Clarus Announces <span style="color: rgb(26, 188, 156)">JATENZO®</span> (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts</strong></span></p><p></p><p></p><p>NORTHBROOK, Ill., Dec. 07, 2020 (GLOBE NEWSWIRE) --<span style="color: rgb(184, 49, 47)"> Clarus Therapeutics, Inc. today announced that Express Scripts, Inc, one of the leading pharmacy benefit managers </span><span style="color: rgb(0, 0, 0)">(PBMs) </span><span style="color: rgb(184, 49, 47)">in the United States will now cover JATENZO® </span><span style="color: rgb(0, 0, 0)">(testosterone undecanoate)</span><span style="color: rgb(184, 49, 47)"> capsules, CIII. JATENZO is the first and only FDA-approved oral testosterone undecanoate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:</span><span style="color: rgb(44, 130, 201)"> Primary hypogonadism </span><span style="color: rgb(0, 0, 0)">(congenital or acquired)</span><span style="color: rgb(44, 130, 201)"> and hypogonadotropic hypogonadism </span><span style="color: rgb(0, 0, 0)">(congenital or acquired)</span><span style="color: rgb(44, 130, 201)">.1,2</span> Important Safety Information, including Boxed Warning, is provided below. Limitations of use: Safety and efficacy of JATENZO in males less than 18 years old have not been established.</p><p></p><p><span style="color: rgb(184, 49, 47)">“This partnership with Express Scripts meaningfully enhances the coverage of JATENZO for patients, and provides appropriate hypogonadal men additional access to an oral testosterone replacement therapy option,”</span> said Dr. Robert Dudley, Chief Executive Officer of Clarus Therapeutics, Inc. <span style="color: rgb(184, 49, 47)">“We believe this improved access to JATENZO will give physicians, and their appropriate patients, a convenient oral option for testosterone replacement therapy, and an alternative, not only for new patients but for those patients who are dissatisfied with their current treatment options.” </span></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">As of December 1, 2020, nearly 99 million commercial lives, or 61.4% of lives in the U.S., now have access to </span><span style="color: rgb(26, 188, 156)">JATENZO</span><span style="color: rgb(184, 49, 47)"> with the addition of <u>Express Scripts</u>.</span></strong> <strong><span style="color: rgb(44, 130, 201)">Clarus is committed to working with payers to further broaden </span><span style="color: rgb(26, 188, 156)">JATENZO</span><span style="color: rgb(44, 130, 201)"> access for patients and to support patients and providers who desire an oral testosterone replacement therapy option. Clarus also offers patients financial assistance through its </span><span style="color: rgb(26, 188, 156)">JATENZO GO</span><span style="color: rgb(44, 130, 201)"> program, where eligible patients with commercial insurance may pay as little as $0 for their monthly prescription of </span><span style="color: rgb(26, 188, 156)">JATENZO</span><span style="color: rgb(44, 130, 201)">. For eligible patients with commercial coverage for </span><span style="color: rgb(26, 188, 156)">JATENZO</span><span style="color: rgb(44, 130, 201)">, their first prescription is free while waiting for insurance verification and prior authorization appeals. Patients can find out more by calling 1-844-269-2795 or visiting the </span><span style="color: rgb(26, 188, 156)">JATENZO </span><span style="color: rgb(44, 130, 201)">website at </span><span style="color: rgb(26, 188, 156)"><a href="https://www.globenewswire.com/Tracker?data=CqLX-zwCfV4X8aVmYeT_1bdoDW2HjUGrOPtBgemuLclh-qEbCMCKKQefjaf4uRBf7pYfEFe_QWbOleKmLlwTUg==" target="_blank">www.Jatenzo.com</a></span><span style="color: rgb(44, 130, 201)"> for all eligibility requirements.</span></strong></p></blockquote><p></p>
[QUOTE="madman, post: 192050, member: 13851"] [URL unfurl="true"]https://www.globenewswire.com/news-release/2020/12/07/2140624/0/en/Clarus-Announces-JATENZO-Testosterone-Undecanoate-Capsules-CIII-Now-Covered-by-Express-Scripts.html[/URL] [SIZE=26px][B]Clarus Announces [COLOR=rgb(26, 188, 156)]JATENZO®[/COLOR] (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts[/B][/SIZE] NORTHBROOK, Ill., Dec. 07, 2020 (GLOBE NEWSWIRE) --[COLOR=rgb(184, 49, 47)] Clarus Therapeutics, Inc. today announced that Express Scripts, Inc, one of the leading pharmacy benefit managers [/COLOR][COLOR=rgb(0, 0, 0)](PBMs) [/COLOR][COLOR=rgb(184, 49, 47)]in the United States will now cover JATENZO® [/COLOR][COLOR=rgb(0, 0, 0)](testosterone undecanoate)[/COLOR][COLOR=rgb(184, 49, 47)] capsules, CIII. JATENZO is the first and only FDA-approved oral testosterone undecanoate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:[/COLOR][COLOR=rgb(44, 130, 201)] Primary hypogonadism [/COLOR][COLOR=rgb(0, 0, 0)](congenital or acquired)[/COLOR][COLOR=rgb(44, 130, 201)] and hypogonadotropic hypogonadism [/COLOR][COLOR=rgb(0, 0, 0)](congenital or acquired)[/COLOR][COLOR=rgb(44, 130, 201)].1,2[/COLOR] Important Safety Information, including Boxed Warning, is provided below. Limitations of use: Safety and efficacy of JATENZO in males less than 18 years old have not been established. [COLOR=rgb(184, 49, 47)]“This partnership with Express Scripts meaningfully enhances the coverage of JATENZO for patients, and provides appropriate hypogonadal men additional access to an oral testosterone replacement therapy option,”[/COLOR] said Dr. Robert Dudley, Chief Executive Officer of Clarus Therapeutics, Inc. [COLOR=rgb(184, 49, 47)]“We believe this improved access to JATENZO will give physicians, and their appropriate patients, a convenient oral option for testosterone replacement therapy, and an alternative, not only for new patients but for those patients who are dissatisfied with their current treatment options.” [/COLOR] [B][COLOR=rgb(184, 49, 47)]As of December 1, 2020, nearly 99 million commercial lives, or 61.4% of lives in the U.S., now have access to [/COLOR][COLOR=rgb(26, 188, 156)]JATENZO[/COLOR][COLOR=rgb(184, 49, 47)] with the addition of [U]Express Scripts[/U].[/COLOR][/B] [B][COLOR=rgb(44, 130, 201)]Clarus is committed to working with payers to further broaden [/COLOR][COLOR=rgb(26, 188, 156)]JATENZO[/COLOR][COLOR=rgb(44, 130, 201)] access for patients and to support patients and providers who desire an oral testosterone replacement therapy option. Clarus also offers patients financial assistance through its [/COLOR][COLOR=rgb(26, 188, 156)]JATENZO GO[/COLOR][COLOR=rgb(44, 130, 201)] program, where eligible patients with commercial insurance may pay as little as $0 for their monthly prescription of [/COLOR][COLOR=rgb(26, 188, 156)]JATENZO[/COLOR][COLOR=rgb(44, 130, 201)]. For eligible patients with commercial coverage for [/COLOR][COLOR=rgb(26, 188, 156)]JATENZO[/COLOR][COLOR=rgb(44, 130, 201)], their first prescription is free while waiting for insurance verification and prior authorization appeals. Patients can find out more by calling 1-844-269-2795 or visiting the [/COLOR][COLOR=rgb(26, 188, 156)]JATENZO [/COLOR][COLOR=rgb(44, 130, 201)]website at [/COLOR][COLOR=rgb(26, 188, 156)][URL='https://www.globenewswire.com/Tracker?data=CqLX-zwCfV4X8aVmYeT_1bdoDW2HjUGrOPtBgemuLclh-qEbCMCKKQefjaf4uRBf7pYfEFe_QWbOleKmLlwTUg==']www.Jatenzo.com[/URL][/COLOR][COLOR=rgb(44, 130, 201)] for all eligibility requirements.[/COLOR][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Jatenzo, an Oral Testosterone Replacement Therapy
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top